Pfizer
PFE
#86
Rank
$149.15 B
Marketcap
$25.86
Share price
-1.82%
Change (1 day)
-37.64%
Change (1 year)

Pfizer Inc., is a global pharmaceutical company headquartered in New York City, New York, United States. It was founded by Charles Pfizer from Ludwigsburg. Pfizer is the second largest pharmaceutical company in the world after Roche, followed by Novartis.

P/E ratio for Pfizer (PFE)

P/E ratio as of April 2024 (TTM): 14.2

According to Pfizer's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.1613. At the end of 2022 the company had a P/E ratio of 9.15.

P/E ratio history for Pfizer from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
20229.15-39.41%
202115.1-34.36%
202023.080.72%
201912.7-41.9%
201821.9128.27%
20179.60-63.56%
201626.3-2.82%
201527.132.06%
201420.5123.88%
20139.17-24.1%
201212.1-24.7%
201116.0-0.55%
201016.115.89%
200913.9-0.6%
200814.0-24.03%
200718.4100.27%
20069.20-54.24%
200520.119.84%
200416.8-67.95%
200352.4167.26%
200219.6-35.21%
200130.2

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
10.6-25.41%๐Ÿ‡บ๐Ÿ‡ธ USA
25.2 78.12%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
37.5 164.79%๐Ÿ‡บ๐Ÿ‡ธ USA
140 887.95%๐Ÿ‡บ๐Ÿ‡ธ USA
19.1 34.74%๐Ÿ‡บ๐Ÿ‡ธ USA
69.2 389.00%๐Ÿ‡บ๐Ÿ‡ธ USA
12.4-12.63%๐Ÿ‡บ๐Ÿ‡ธ USA
35.0 147.06%๐Ÿ‡ฌ๐Ÿ‡ง UK
11.7-17.70%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.